Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25411664 | 0.99 | CYP3A4 (0.57) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL26313653 | 0.88 | TSHR (0.52) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL25411335 | 0.86 | CYP3A4 (0.47) | CYP3A4NOS2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL25411663 | 0.85 | TSHR (0.45) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL25411640 | 0.85 | TSHR (0.44) | CYP3A4TSHRNOS2ALDH1A1HTT | |
| SCHEMBL25412807 | 0.83 | TSHR (0.42) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL26313667 | 0.82 | TSHR (0.47) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL25411012 | 0.81 | TSHR (0.41) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL25413416 | 0.81 | TSHR (0.41) | CYP3A4TSHRNOS2CYP2D6SLC6A2 | |
| SCHEMBL25413679 | 0.81 | CYP3A4 (0.59) | CYP3A4TSHRALDH1A1ADRA2CRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | CYP3A4 73/4885TSHR 990/4885NOS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.